BALTIC16 Damber speaking

BALTIC16: Resistance potential and QoL issues in mCRPC patients

There are small gains made in the hormone and chemo-treatment of metastatic castration-resistant prostate cancer (mCRPC) but experts caution that the increased use of these new agents may lead to new patterns of resistance. “With increasing use of novel...
young uro comp 2

Baltic16: Quality of life in prostate cancer patients

Issues in diagnosing and treating prostate cancer particularly in patients with resistant or metastatic disease were taken up in several sessions at the 3rd EAU Baltic Meeting with experts saying that although there are new and emerging options a careful selection...
More than 300 participants gather in Tallinn for the 3rd EAU Baltic Meeting

Baltic16: EAU to boost collaboration with Baltic region

The 3rd EAU Baltic Meeting opened today in Tallinn with more than 300 registered participants  and experts from and outside the region examining a range of challenges and prospects in the diagnosis and treatment of prostate, bladder and kidney...